ProQR Q2 revenue and EPS miss estimates

Reuters08-07

ProQR <a href="https://laohu8.com/S/QTWO">Q2</a> revenue and EPS miss estimates

Overview

ProQR Q2 revenue and EPS miss analysts' expectations, per LSEG data
Co submitted CTA for AX-0810, targeting NTCP for cholestatic diseases
ProQR holds EUR119.8 mln cash, providing runway into mid-2027

Outlook

ProQR expects initial AX-0810 Phase 1 data in Q4 2025
Company anticipates AX-2402 clinical candidate selection in 2025
ProQR's cash runway extends into mid-2027, excluding Lilly milestones

Result Drivers

LILLY PARTNERSHIP - Achieved milestones in collaboration with Eli Lilly, contributing €1.8 mln to revenue

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue	Miss	EUR 3.82 mln	EUR 4.45 mln (7 Analysts)
Q2 EPS	Miss	-EUR 0.12	-EUR 0.08 (7 Analysts)
Q2 Net Income	Miss	-EUR 12.18 mln	-EUR 8.99 mln (6 Analysts)
Q2 Operating Income	Miss	-EUR 12.25 mln	-EUR 8.77 mln (5 Analysts)
Q2 Basic EPS		-EUR 0.12

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 77.1% above its August 6 closing price of $2.06

Press Release: ID:nGNE8yKjqm

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2557557846?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557557846","market":"nz","top_or_hot":-1,"title":"ProQR Q2 revenue and EPS miss estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ProQR <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue and EPS miss estimates</title></head><body><p><span>Overview</span></p><ul><li><p>ProQR Q2 revenue and EPS miss analysts' expectations, per LSEG data</p></li><li><p>Co submitted CTA for AX-0810, targeting NTCP for cholestatic diseases</p></li><li><p>ProQR holds EUR119.8 mln cash, providing runway into mid-2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>ProQR expects initial AX-0810 Phase 1 data in Q4 2025</p></li><li><p>Company anticipates AX-2402 clinical candidate selection in 2025</p></li><li><p>ProQR's cash runway extends into mid-2027, excluding Lilly milestones</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LILLY PARTNERSHIP - Achieved milestones in collaboration with Eli Lilly, contributing €1.8 mln to revenue</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Miss</p></td><td><p>EUR 3.82 mln</p></td><td><p>EUR 4.45 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Miss</p></td><td><p>-EUR 0.12</p></td><td><p>-EUR 0.08 (7 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Miss</p></td><td><p>-EUR 12.18 mln</p></td><td><p>-EUR 8.99 mln (6 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Miss</p></td><td><p>-EUR 12.25 mln</p></td><td><p>-EUR 8.77 mln (5 Analysts)</p></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-EUR 0.12</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for ProQR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> NV is $9.00, about 77.1% above its August 6 closing price of $2.06</p></li></ul><p>Press Release: <span>ID:nGNE8yKjqm</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProQR Q2 revenue and EPS miss estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProQR Q2 revenue and EPS miss estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-07 19:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ProQR <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue and EPS miss estimates</title></head><body><p><span>Overview</span></p><ul><li><p>ProQR Q2 revenue and EPS miss analysts' expectations, per LSEG data</p></li><li><p>Co submitted CTA for AX-0810, targeting NTCP for cholestatic diseases</p></li><li><p>ProQR holds EUR119.8 mln cash, providing runway into mid-2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>ProQR expects initial AX-0810 Phase 1 data in Q4 2025</p></li><li><p>Company anticipates AX-2402 clinical candidate selection in 2025</p></li><li><p>ProQR's cash runway extends into mid-2027, excluding Lilly milestones</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LILLY PARTNERSHIP - Achieved milestones in collaboration with Eli Lilly, contributing €1.8 mln to revenue</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Miss</p></td><td><p>EUR 3.82 mln</p></td><td><p>EUR 4.45 mln (7 Analysts)</p></td></tr><tr><td><p>Q2 EPS</p></td><td><p>Miss</p></td><td><p>-EUR 0.12</p></td><td><p>-EUR 0.08 (7 Analysts)</p></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Miss</p></td><td><p>-EUR 12.18 mln</p></td><td><p>-EUR 8.99 mln (6 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Miss</p></td><td><p>-EUR 12.25 mln</p></td><td><p>-EUR 8.77 mln (5 Analysts)</p></td></tr><tr><td><p>Q2 Basic EPS</p></td><td></td><td><p>-EUR 0.12</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for ProQR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> NV is $9.00, about 77.1% above its August 6 closing price of $2.06</p></li></ul><p>Press Release: <span>ID:nGNE8yKjqm</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRQR","symbol_name":"ProQR Therapeutics N.V.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX950AE4:1","article_id":"2557557846","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557557846","pubTimestamp":1754564895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ProQR Q2 revenue and EPS miss estimatesOverviewProQR Q2 revenue and EPS miss analysts' expectations, per LSEG dataCo submitted CTA for AX-0810, targeting NTCP for cholestatic diseasesProQR holds EUR11","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PRQR":"ProQR Therapeutics N.V."},"translate_title":"ProQR第二季度收入和每股收益未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRQR":0.9},"content_text":"ProQR Q2 revenue and EPS miss estimatesOverviewProQR Q2 revenue and EPS miss analysts' expectations, per LSEG dataCo submitted CTA for AX-0810, targeting NTCP for cholestatic diseasesProQR holds EUR119.8 mln cash, providing runway into mid-2027OutlookProQR expects initial AX-0810 Phase 1 data in Q4 2025Company anticipates AX-2402 clinical candidate selection in 2025ProQR's cash runway extends into mid-2027, excluding Lilly milestonesResult DriversLILLY PARTNERSHIP - Achieved milestones in collaboration with Eli Lilly, contributing €1.8 mln to revenueKey DetailsMetricBeat/MissActualConsensus EstimateQ2 RevenueMissEUR 3.82 mlnEUR 4.45 mln (7 Analysts)Q2 EPSMiss-EUR 0.12-EUR 0.08 (7 Analysts)Q2 Net IncomeMiss-EUR 12.18 mln-EUR 8.99 mln (6 Analysts)Q2 Operating IncomeMiss-EUR 12.25 mln-EUR 8.77 mln (5 Analysts)Q2 Basic EPS-EUR 0.12Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 77.1% above its August 6 closing price of $2.06Press Release: ID:nGNE8yKjqm(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557557846","isCrawlerRequest":true}